The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 28, 2025

Filed:

Jun. 10, 2022
Applicant:

The Johns Hopkins University, Baltimore, MD (US);

Inventors:

Bert Vogelstein, Baltimore, MD (US);

Kenneth W. Kinzler, Baltimore, MD (US);

Nickolas Papadopoulos, Towson, MD (US);

Isaac A. Kinde, Beaumont, CA (US);

Assignee:

The Johns Hopkins University, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6874 (2018.01); C12Q 1/6806 (2018.01); C12Q 1/6869 (2018.01); C12Q 1/6876 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6874 (2013.01); C12Q 1/6806 (2013.01); C12Q 1/6869 (2013.01); C12Q 1/6876 (2013.01); C12Q 2525/179 (2013.01); C12Q 2525/191 (2013.01); C12Q 2563/179 (2013.01); C12Q 2600/158 (2013.01);
Abstract

The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called 'Safe-SeqS' for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ≥95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.


Find Patent Forward Citations

Loading…